Gene · 10213
PSMD14: proteasome 26S subunit, non-ATPase 14
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMD14: proteasome 26S subunit, non-ATPase 14. Genes, record 10213. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/10213
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O00487 | Ubiquitin C-terminal hydrolase PSMD14 | 310 | 129 | Ensembl, GeneID, HGNC |
Source UniProt
Patents47
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 59472 | O00487 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 12061 | O00487 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 12061 | O00487 | Espacenet |
| US 11925690 B2 | 2024-03-12 | 2 | O00487 | Espacenet |
| JP 2023551068 A | 2023-12-06 | 99 | O00487 | Espacenet |
| JP 2023549761 A | 2023-11-29 | 99 | O00487 | Espacenet |
| JP 2023549167 A | 2023-11-22 | 99 | O00487 | Espacenet |
| JP 2023548973 A | 2023-11-21 | 99 | O00487 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67763 | O00487 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170734 | O00487 | Espacenet |
1 to 10 of 47
See all 47 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,229
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,229
See all 1,229 trialsNIH grants787
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMD14 papers | Newest fiscal year |
|---|---|---|---|
| ZIABC011490 | Maintaining cell health by targeted protein degradation | 8 | 2025 |
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 6 | 2025 |
| P30CA022453 | CANCER CENTER SUPPORT GRANT | 4 | 2025 |
| R01GM065334 | Solution structure and dynamics of polyubiquitin chains | 4 | 2025 |
| P01CA155258 | Integrative Oncogenomics of Multiple Myeloma | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| ZICES102445 | Gene Expression and Microarrays | 3 | 2025 |
| P01AI169768 | High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir | 2 | 2025 |
| P01CA092584 | Structural Cell Biology of DNA Repair Machines | 2 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
1 to 10 of 787Source NIH's project files
See all 787 nih grantsPapers1,284
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PSMD14 as a translational target in cancer and beyond: from deubiquitination mechanisms to drug resistance and precision therapy. | Cancer Drug Resist | 2026 | 42729688 | PubTator, text mining | PubMed |
| C646-loaded mesenchymal stromal cell extracellular vesicles alleviate lactate-driven immunoparalysis in sepsis-associated ARDS through the p300-H3K18la-PSMD14 axis. | Int Immunopharmacol | 2026 | 42673886 | PubTator, text mining | PubMed |
| Amelioration of nonalcoholic fatty liver disease by inhibiting the deubiquitylating enzyme RPN11. | Cell Metab | 2026 | 42492517 | PubTator, text mining | PubMed |
| Prognostic and therapeutic implications of PSMD14 in hepatocellular carcinoma: an integrative analysis of transcriptomic and single-cell profiles. | Transl Cancer Res | 2026 | 42445433 | PubTator, text mining | PubMed |
| CDW19S coordinates phasic end processing via distinct enzymatic activities. | Nucleic Acids Res | 2026 | 42406631 | PubTator, text mining | PubMed |
| Acid-responsive cobalt-doped ZIF-8 nanoplatform potentiates ferroptosis in osteosarcoma by disrupting the PSMD14/SLC7A11 axis. | Biomater Adv | 2026 | 42287937 | PubTator, text mining | PubMed |
| Integrative analysis of bulk and single-nucleus transcriptomes suggests proteostasis- and metabolism-related alterations in the right ventricular outflow tract of non-syndromic Tetralogy of Fallot. | Funct Integr Genomics | 2026 | 42230411 | PubTator, text mining | PubMed |
| DUSP4-mediated dephosphorylation of PSMD14 enhances PSMD14-dependent deubiquitination of MICALL2 and promotes malignant progression in clear cell renal cell carcinoma. | J Transl Med | 2026 | 42174657 | PubTator, text mining | PubMed |
| Targeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer. | J Exp Clin Cancer Res | 2026 | 41981629 | PubTator, text mining | PubMed |
| Structural dynamics of the midnolin-proteasome during ubiquitin-independent substrate turnover. | Nat Commun | 2026 | 41896529 | PubTator, text mining | PubMed |
1 to 10 of 1,284
See all 1,284 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/10213
GET https://conductscience.org/api/genes/v1/10213/patents?page=2